Skip to content

Author

A. Zaenglein

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.

Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.

A. Paller, L. Stein Gold, E. Simpson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.